A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter. READ MORE
Research in Review
Researchers compared a treatment regimen including bortezomib with standard care practices to see which would be more cost effective for patients with mantle cell lymphoma.
Findings from a single-center analysis have shown that anthracycline-based therapies may produce better outcomes in patients age 80 years and older with diffuse large B-cell lymphoma (DLBCL), supporting data reported in previous clinical trials.
In a study published in the Journal of Clinical Oncology, researchers investigated the utility of PET imaging to guide response-adapted therapy for patients with advanced Hodgkin lymphoma.
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial.